Journal
DRUG DEVELOPMENT RESEARCH
Volume 70, Issue 2, Pages 94-100Publisher
WILEY-BLACKWELL
DOI: 10.1002/ddr.20288
Keywords
Alzheimer's disease; beta-Amyloid cascade hypothesis; gamma-secretase; gamma-secretase inhibitors; Notch
Categories
Ask authors/readers for more resources
Alzheimer's disease is a neurodegenerative disorder manifested by cognitive and memory deterioration, impairment of language, and other activities of daily life. Two major pathological hallmarks are characteristics of Alzheimer's disease: intracellular neurofibrillary tangles and extracellular amyloid plaques. The amyloid plaque is mainly comprised of aggregated form of the 40-42 residue amyloid beta-peptide (A beta). The accumulation and deposition of A beta eventually lead to neuronal damage and cell death. A beta peptides are generated from a large precursor protein (APP) by beta-secretase (BACE) and gamma-secretase. Reduction of A beta by inhibition of gamma-secretase may prevent A beta-mediated downstream neurotoxic events, representing an attractive strategy to combat Alzheimer's disease. gamma-Secretase is a multi-component complex comprised of four distinct units: presenilin, nicastrin, aph-1, and pen2. In addition to processing APP, gamma-secretase has also been implicated in the cleavage of other substrates, the most notable one being the Notch receptor. Inhibition of Notch processing is the key factor of mechanism-based side effects associated with gamma-secretase inhibitors. It is imperative to balance the therapeutic efficacy and the risk of mechanism-based toxicity. Drug Dev Res 70: 94-100, 2009. (C) 2009 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available